Sign up for a free trial now
  • Login
  • Subscribe
  • Take a FREE Trial
  • About Us
  • Contact us
  • RSS

20 June 2013


The Pharma Letter
  • Home
  • 7 Day Premium Trial
  • Pharmaceuticals
  • Biotechnology
  • Generics
  • Events
  • Companies
  • Drugs
  • Subscribe

Olux Articles

GSK to buy US derma co Steifel for $2.9B+

20 April 2009

Clobex/Vectical "effective" in managing psoriasis

16 March 2009

Ventiv in new partnership with Connetics

25 April 2005

FDA advisers mull requirements for topical corticosteroids OTC switch

11 April 2005

Connetics start Ph III program for steroid

4 April 2005

Connetics gives guidance for 1st-qtr

19 April 2004

Connetics sees 4th-qtr product revenues rise 50%

3 February 2003

Connetics profitable by "2nd-half 2003"

24 June 2002

Mipharm files for OLUX approval in UK

29 April 2002

Connetics files for expanded use of Olux

11 March 2002

Taro Pharma raises $128 million

8 October 2001

Miza signs supply deal with Connetics

21 September 2001

Dura gets rights to GW's dermatalogy line

3 October 2000

Connetics gains US approval for Olux

1 June 2000

Connetics files NDA for Olux

3 August 1999

Alpharma gets generics approval

15 January 1996

Showing 1-16 of 16 articles

Go to beginningPrevious
  • 1
NextGo to end
  • Hot Topics
  • Most Read
  • Aspen Pharma offers to buy GlaxoSmithKline's thrombosis brands and manufacturing site
  • US Supreme Court says patent settlement can "sometimes" be illegal
  • Athera and Boehringer Ingelheim enter option agreement on a novel therapy for atherosclerosis
  • FDA probes two deaths possibly linked to Lilly's antipsychotic Zyprexa Relprevv
  • Australia's pharma industry applauds R&D regulatory reform
  • Aspen Pharma offers to buy GlaxoSmithKline's thrombosis brands and manufacturing site
  • US Supreme Court says patent settlement can "sometimes" be illegal
  • Athera and Boehringer Ingelheim enter option agreement on a novel therapy for atherosclerosis
  • FDA probes two deaths possibly linked to Lilly's antipsychotic Zyprexa Relprevv
  • Australia's pharma industry applauds R&D regulatory reform

30 Day Premium Trial


Events

Twitter Right banner

RSS



© 2013 thepharmaletter.com

  • Home
  • RSS
  • About Us
  • Subscribe
  • Terms and Conditions
  • Article Archive
Site powered by WORKSsitebuilder CMS